Valens: Analysts Reiterate Price Targets, Ratings Following Q3 Results

Last week, The Valens Company (TSX: VLNS) reported their third-quarter results. Revenues were stable quarter over quarter at $18.1 million, barely below the consensus of $18.4 million. The results were above Stifel’s estimate of $17.7 million but a notable miss from Raymond James estimate of $19.9 million. Valens had a $504 thousand write down this quarter compared to the $1.5 million in inventory write-downs they took during the second quarter of 2020.

Andrew Partheniou of Stifel headlines “In-line Q3FY20 – still early innings for VLNS.” Valens launched eight new products between vapes and concentrates during this quarter, but Partheniou says that now the focus has moved to fulfilling retail demand and capturing market share. Partheniou adds that Valens vape offerings account for 4 out of the top 15 brands in the Ontario market in dollar terms, for the period ending in September. He says, “matched with management indicating provincial orders are accelerating from initial smaller orders, we are encouraged by the company’s early progress thus far.”

Partheniou comments that Valens is “remaining conservative on tolling demand” as the fall harvest is currently happening. He expects some seasonal demand to come back to Valens tolling services. Still, he remains warry as companies have bad balance sheets, and Valens is trying not to take on every co’s tolling agreement due to their risk aversion policy.

Partheniou says that input prices might go lower with the harvest of outdoor crops and adds, “we envision VLNS benefitting from this years’ outdoor harvest through higher margins. Nevertheless, this may take some time to flow through the company’s P&L as it works through its roughly ~6 months of inventory.”

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Stifel reiterated their C$3.75 price target and buy rating on Valens.

In Raymond James’ note, Rahul Sarugaser reiterated the same idea’s and comments as Partheniou did. Still, one thing Sarugaser pointed out that wasn’t in Stifel’s note was that Valens new facility “K2” is being brought online, which will be a short term cash drain as commissioning is performed. Start-up inefficiencies tend to happen when new facilities are starting for the first time.

Raymond James has a C$3.50 price target and a market perform rating on Valens.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A $2.2B Gold Project Is Outgrowing Its Plan | Michael Henrichsen – Gold X2 Mining

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Recommended

Rackla Metals Adds Two Northern Development Veterans to Board as Lentung Advances

Northmin Hits 12.85% Copper and 933 g/t Silver in Highest Grade Tynagh Assays Yet

Related News

Raymond James: Village Farms Selloff Is Overdone

Village Farms International, Inc. (TSX: VFF) investors are having a rough start to the month,...

Wednesday, May 12, 2021, 02:36:00 PM

Great Bear: Canaccord Model Is Based On “Initial Applied Resource Of 4 Million Gold Ounces”

Yesterday, Great Bear Resources (TSXV: GBR) reported results from its ongoing exploration program at their...

Thursday, December 10, 2020, 11:21:00 AM

Trulieve: Canaccord Retains $97 Price Target Following Harvest Health Transaction

On October 1, Trulieve Cannabis (CSE: TRUL) announced that they completed their $1.75 billion acquisition...

Sunday, October 10, 2021, 01:03:00 PM

Organigram Holdings: Numerous Analysts Cut Price Targets On Poor Earnings

Yesterday, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) released its financial statements for the third quarter...

Wednesday, July 22, 2020, 04:58:34 PM

Columbia Care: Canaccord Reiterates Top Pick Following Green Leaf Medical Acquisition

Last Friday, Columbia Care Inc. (CSE: CCHW) closed their acquisition of Green Leaf Medical which...

Friday, June 18, 2021, 01:30:00 PM